SIN3A is a transcriptional corepressor that functions primarily through histone deacetylation and chr15 remodeling 1. It mediates transcriptional repression by interacting with histone deacetylase complexes and associates with multiple regulatory proteins to suppress gene expression 1. In circulating tumor cell clusters, SIN3A binding sites are hypomethylated, correlating with enhanced stemness and metastatic potential 2. Disease relevance of SIN3A dysfunction is increasingly recognized. Loss of SIN3A in alveolar type 2 cells triggers p53-dependent cellular senescence and spontaneous progressive pulmonary fibrosis in mice, identifying senescence as a key pathogenic mechanism 3. Conversely, SIN3A overexpression demonstrates therapeutic potential in pulmonary arterial hypertension by preventing BMPR2 promoter methylation through downregulation of methyltransferases (DNMT1, EZH2) and upregulation of demethylase TET1, with adeno-associated virus-mediated SIN3A delivery attenuating pulmonary vascular remodeling in preclinical models 4. Additionally, SIN3A participates in repressive complexes containing MECP2 and HDAC1 that regulate neuroinflammation through PU.1 motif targeting, with therapeutic implications for neurodegenerative diseases 5. These findings position SIN3A as a critical epigenetic regulator with context-dependent roles in disease pathogenesis and potential as a therapeutic target across multiple organ systems.